SCHEMBL1132701

SCHEMBL1132701

O=[N+]([O-])c1ccc(NN=Cc2ccc(O)c(O)c2)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 11/20 0.75
KMT2A Q03164 11/20 0.75
RAB9A P51151 3/20 0.75
TLR9 Q9NR96 1/20 0.75
NPC1 O15118 4/20 0.63
MAPT P10636 3/20 0.63
MAPK1 P28482 2/20 0.63
KDM4E B2RXH2 2/20 0.63
ALDH1A1 P00352 1/20 0.63
CASP3 P42574 1/20 0.61
SENP8 Q96LD8 1/20 0.61
SENP7 Q9BQF6 1/20 0.61
SENP6 Q9GZR1 1/20 0.61
POLB P06746 4/20 0.59
GAA P10253 4/20 0.59
CCR6 P51684 1/20 0.59
RRM1 P23921 2/20 0.57
NOX4 Q9NPH5 2/20 0.54
LMNA P02545 2/20 0.51
BLM P54132 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1132698 1.00 MEN1 (0.75) MEN1KMT2ARAB9ATLR9NPC1
SCHEMBL19244893 0.84 MEN1 (0.73) MEN1KMT2ARAB9ATLR9NPC1
SCHEMBL1132554 0.82 MEN1 (0.71) MEN1KMT2ARAB9ATLR9NPC1
SCHEMBL1132103 0.82 MEN1 (0.71) MEN1KMT2ARAB9ATLR9NPC1
SCHEMBL28689490 0.82 KMT2A (0.73) MEN1KMT2ARAB9ATLR9NPC1
SCHEMBL10421074 0.78 MEN1 (0.61) MEN1KMT2ARAB9ATLR9NPC1
SCHEMBL12218394 0.78 KMT2A (0.73) MEN1KMT2ARAB9ATLR9NPC1
SCHEMBL28072285 0.78 MEN1 (0.73) MEN1KMT2ARAB9ATLR9NPC1
SCHEMBL27898236 0.78 MEN1 (0.73) MEN1KMT2ARAB9ATLR9NPC1
SCHEMBL10421075 0.78 MEN1 (0.73) MEN1KMT2ARAB9ATLR9NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9512066-B2 Enhancers of protein degradation MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) 2016-12-06 US claimed
US-20120282629-A1 Enhancers of Protein Degradation MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) 2012-11-08 US claimed
EP-2287149-A1 Enhancers of protein degradation MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) 2011-02-23 EP claimed
US-9512066-B2 Enhancers of protein degradation MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) 2016-12-06 US disclosed
US-20120282629-A1 Enhancers of Protein Degradation MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) 2012-11-08 US disclosed
EP-2488485-A1 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2012-08-22 EP disclosed
WO-2011020883-A9 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2012-07-12 WO disclosed
WO-2011020883-A1 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2011-02-24 WO disclosed
EP-2287149-A1 Enhancers of protein degradation MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) 2011-02-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120282629-A1 Enhancers of Protein Degradation HTT, HYPK, TFEB MEN1 3413/4885KMT2A 2000/4885RAB9A 2389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.